RxDoctor Payments Data

Cesar Rodriguez, MD

Family Medicine · Albuquerque, NMNPI 1124368055

Payments from drug & device makers

$253in general payments, 2019–2025

Across 14 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$81
  • Mannkind Corporation$43
  • Boehringer Ingelheim$42
  • Sanofi-aventis U.S. LLC$19
  • Johnson & Johnson$16
  • GSK$15
  • plus $37 from 3 others

What the payments were for

  • Food & beverage$21083%
  • Education$4317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$253 in reported general payments places this provider in the 60th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$54,919
Medicare patients
189
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$145,270
JardianceEmpagliflozin87$112,784
EliquisApixaban62$77,417
MounjaroTirzepatide42$46,883
XareltoRivaroxaban32$29,352
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$27,417
MyrbetriqMirabegron38$20,064
JanuviaSitagliptin Phosphate13$18,843
Spiriva RespimatTiotropium Bromide24$14,433
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$11,949
Breo ElliptaFluticasone/Vilanterol26$10,949
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,100
Testosterone30$10,030
Atorvastatin Calcium641$8,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81$145,27094 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$42$137,696128 claims
PfizerEliquis$12$77,41762 claims
Johnson & JohnsonXarelto$16$29,35232 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$15$25,57653 claims
Astellas Pharma US IncMyrbetriq$13$20,06438 claims
AstraZenecaBreztri Aerosphere$12$6,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →